Grant: Engage Grants Program
McMaster University
$25,000.00
Expanding the role of P-31 NMR in the study of phosphate-acting enzymes
EF 2018-19
Résumé
Bruker is the world leader in nuclear magnetic resonance (NMR) spectrometers, and is keen to expand its*presence in catalysis and enzyme inhibition research. Many pharmaceutical targets are enzymes that*chemically transform phosphate-containing compounds. Twelve kinase inhibitor drugs are already used in*cancer chemotherapy, and >100 more in are clinical trials. Detailed understanding of enzyme mechanisms*greatly aids new inhibitor design: the flu drugs oseltamivir and zanamivir, and the cancer drug forodesine were*all designed after determining the target enzymes' transition state (TS) structures. The TS is the top of the*energetic barrier that enzymes must surmount for a reaction to occur. Enzymes bind TSs extremely tightly,*making TS mimics potent inhibitors. However, determining TS structures is technically demanding; it requires*measuring the effects of isotopic labels on reaction rates, effects that are frequently < 1%. Recent advances in*NMR spectroscopy have brought the instrumentation for these measurements within reach of most labs, but the*methods needed to exploit these new capabilities remain under-developed. We propose a combined physical*chemistry / applied enzymology study to develop methods to use phosphorus-31 (31P) NMR to measure*isotope effects. This represents an opportune combination of expertise, with Bruker Canada providing the*NMR expertise while the Berti lab providing expertise in TS analysis. Bruker Canada will directly benefit*from the development of new methods that will become part of their applications library. Both private sector*and academic labs will be able to take advantage of the expanded repertoire of NMR techniques to determine*TS structures, expanding the utility of NMR spectroscopy for non-specialist labs. Bruker Canada will also*benefit from direct access to sample preparation, HQP and the NMR spectrometers available at McMaster for*both development and demonstrations for potential customers. The proposed NMR experiments are expected*to attract the interest of other academic laboratories working on inhibitor design and reaction mechanisms. The*proposed work will therefore expand Bruker Canada's customer base in both the private and public sectors.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
529394-2018
Name nom
Berti, Paul
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3404
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Biophysical chemistry
Research subject fr
Chimie biophysique
Partie
1
Nb partie
1
Application title
Expanding the role of P-31 NMR in the study of phosphate-acting enzymes
Keyword
NSERC
Application summary
Bruker is the world leader in nuclear magnetic resonance (NMR) spectrometers, and is keen to expand its*presence in catalysis and enzyme inhibition research. Many pharmaceutical targets are enzymes that*chemically transform phosphate-containing compounds. Twelve kinase inhibitor drugs are already used in*cancer chemotherapy, and >100 more in are clinical trials. Detailed understanding of enzyme mechanisms*greatly aids new inhibitor design: the flu drugs oseltamivir and zanamivir, and the cancer drug forodesine were*all designed after determining the target enzymes' transition state (TS) structures. The TS is the top of the*energetic barrier that enzymes must surmount for a reaction to occur. Enzymes bind TSs extremely tightly,*making TS mimics potent inhibitors. However, determining TS structures is technically demanding; it requires*measuring the effects of isotopic labels on reaction rates, effects that are frequently < 1%. Recent advances in*NMR spectroscopy have brought the instrumentation for these measurements within reach of most labs, but the*methods needed to exploit these new capabilities remain under-developed. We propose a combined physical*chemistry / applied enzymology study to develop methods to use phosphorus-31 (31P) NMR to measure*isotope effects. This represents an opportune combination of expertise, with Bruker Canada providing the*NMR expertise while the Berti lab providing expertise in TS analysis. Bruker Canada will directly benefit*from the development of new methods that will become part of their applications library. Both private sector*and academic labs will be able to take advantage of the expanded repertoire of NMR techniques to determine*TS structures, expanding the utility of NMR spectroscopy for non-specialist labs. Bruker Canada will also*benefit from direct access to sample preparation, HQP and the NMR spectrometers available at McMaster for*both development and demonstrations for potential customers. The proposed NMR experiments are expected*to attract the interest of other academic laboratories working on inhibitor design and reaction mechanisms. The*proposed work will therefore expand Bruker Canada's customer base in both the private and public sectors.